601607 上海醫藥
按盤價 
21.070 -0.100 (-0.472%) | 2024/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 209,628,734 | 6.14% | 260,295,089 | 231,981,300 | 215,824,259 | 191,909,156 | |
| 減：營業總成本 | 203,433,368 | 6.30% | 253,008,864 | 224,907,251 | 209,641,475 | 185,559,849 | |
| 其中:營業成本 | 186,451,658 | 7.44% | 228,966,947 | 201,494,923 | 187,281,149 | 165,180,104 | |
| 財務費用 | 1,149,185 | -0.45% | 1,485,758 | 1,313,192 | 1,245,369 | 1,239,584 | |
| 資產減值損失 | (64,752) | -290.94% | (561,277) | (331,471) | (140,441) | (898,616) | |
| 公允價值變動收益 | 142,203 | -40.51% | 404,731 | 218,738 | (206,004) | 116,798 | |
| 投資收益 | 343,493 | -509.78% | (68,123) | 533,117 | 1,811,394 | 976,195 | |
| 其中：對聯營企業和合營企業的投資收益 | 447,826 | 398.03% | 129,329 | 526,743 | 789,596 | 1,009,547 | |
| 營業利潤 | 6,668,767 | 1.72% | 7,667,235 | 9,014,650 | 8,205,486 | 7,184,388 | |
| 利潤總額 | 6,644,377 | 1.92% | 7,054,297 | 8,808,353 | 8,143,815 | 7,175,483 | |
| 減：所得稅費用 | 1,621,079 | 3.57% | 1,887,726 | 1,816,339 | 1,869,245 | 1,570,219 | |
| 淨利潤 | 5,023,298 | 1.40% | 5,166,570 | 6,992,015 | 6,274,569 | 5,605,264 | |
| 減：非控股權益 | 969,120 | -16.24% | 1,398,571 | 1,374,863 | 1,181,102 | 1,109,047 | |
| 股東淨利潤 | 4,054,178 | 6.78% | 3,768,000 | 5,617,152 | 5,093,467 | 4,496,217 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 1.090 | 5.83% | 1.020 | 1.610 | 1.790 | 1.580 | |
| 每股派息 (元) * | 0.080 | -- | 0.410 | 0.610 | 0.420 | 0.480 | |
| 每股淨資產 (元) * | 19.129 | 3.40% | 18.500 | 18.137 | 17.367 | 15.958 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 30/12/2024 11:15 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
